Cancer targeted therapy involves administering drugs that selectively bind to and inhibit cancer-specific targets, thereby limiting adverse effects on normal cells. The Nordic Cancer Targeted Therapy Market share is expected to reach US$ 3,117.4 million by 2031 from US$ 1,510.0 million in 2024. The market is estimated to record a CAGR of 10.9% from 2025 to 2031. The rising...